Tobacco is a risk factor for hidradenitis suppurativa (HS). Korean population study finds 3761 HS out of 6 million. Those who quit smoking developed less HS (adj HR 0.68; 95% CI, 0.56-0.83) https://t.co/4HF0Z5HORk https://t.co/ZilX4EzAa9

Biologic Rx may be less effective in psoriasis pts who are older, smokers, w/ Hi BMI & prior biologic use. Metanalysis of 40 studies, 21 438 PSO pts, and PASI90 responses. Decr Response w/ age (OR 0.99), Biologics (0.44), BMI 30+ (0.57), smoking (0.81) https://t.co/uhFFIwNKB7 https://t.co/LaznQ0M9UG

Predictors of Pregnancy Outcomes in SLE A review of preconception predictors of pregnancy outcomes in women with SLE highlighted lupus nephritis,chronic hypertension, SLE disease activity and secondary antiphospholipid syndrome as predictors of APO. https://t.co/vA445kSe5t https://t.co/wGhLjCmJ3v

Pulse Steroids with Tocilizumab in Giant Cell Arteritis A pilot study assessed pulse methoprednisolone with weekly subcutaneous TCZ in patients with large vessel-GCA (LV-GCA) and showed that a sizeable minority will relapse after the TCZ is discontinued. https://t.co/gGrSY3U1t9 https://t.co/zuspadaY9t

Overview of Cannabinoids for Rheumatic Pain disappoints because not much is really known or studied well. They may improve pain, but come w/ mild-mod side effects. Conflicting evidence contributes to practitioner and patient uncertainty https://t.co/eI07SXbbem https://t.co/ZDvdFcLXh4

HBV reactivation w/ Anti-IL17, IL12/23, IL23 & JAKi. Metanalysis of pts w/ chronic HBV infection (HBsAg+ or detectable HBV-DNA) and prior HBV infection (HBcAb+, HBsAg neg) shows more reactiv w/ chronic HBV (14% vs 5%), similar betw classes (0-4%) https://t.co/5Jgehb5gNg https://t.co/o0TuLEsMm9

#Injection of PIP Mid joint capsule but above midline to avoid collateral ligament #ClinicalPearl #MedTwitter #MedEd #RheumX #RheumEd #MedX https://t.co/N9dBHB0rsf

JAKi an option for Still's Dz, especially refractory AOSD? Metanlysis of 9 studies (35 pts), Rx w/ either Tofa (17), Bari (14), Ruxo (4), Upa 1. Half had complete remission, 1/3 partial remission, 1/5 loss effect. Ruxolitinib 100% effective in AOSD w/ MAS https://t.co/3TKFNsj4v9 https://t.co/3yAXlcJ2sX

ACR Applauds Lower Negotiated Prices for Common Arthritis Drugs The ACR praised the recent announcement from the CMS that their initial drug pricing negotiations have reduced costs for select medications, including significantly lower prices for Enbrel and Stelara, which are… https://t.co/GXl6y87ZaF https://t.co/A2N4Ehg8Dk

Severe Alopecia Areata or Universalis - if you stop the JAK inhibitor, Hair loss occurs quickly, but can be recaptured. Severe Alopecia Areata. Substudy of the baricitinib BRAVE-AA1 RCT, 80% of those who D/C vs 8% of those continuing, lost BARI benefits https://t.co/YcfmegdvK6 https://t.co/GIwVy4ac6U

Global Biologics Market size is valued at USD 408.5 billion in 2023 and is projected to grow ~8.25% annually. https://t.co/2RTHIgJOP5 https://t.co/gfndut5wc0

Higher Cancer Rates (8.16.2024) Dr. Jack Cush reviews the news and journal reports from the past week on https://t.co/V10S4oVFsv, noting his concerns about diet, cancer, ILD, death and dosing challenges. https://t.co/thNOPkYWRM https://t.co/ZFwvE80e7Q